Prospective, Non-interventional, 2-year Post-authorization Safety Study for QLAIRA
Phase of Trial: Phase IV
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Estradiol valerate/dienogest (Primary)
- Indications Pregnancy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer
- 18 Sep 2015 Planned End Date changed from 1 Sep 2017 to 1 Jul 2018 as reported by ClinicalTrials.gov record.
- 18 Sep 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
- 19 Aug 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.